Field Force BP Lead - Genmed
About the job
- A minimum bachelor's degree is required; an advanced degree such as a master's, PhD, or MBA is preferred.
- At least 6 years of rich FFE, field force management, or business consulting experience in healthcare, pharmaceutical, or related healthcare industries is required; specialty care experience is strongly preferred.
- Project management experience is required; change management experience with FFE transformation or evolution is preferred.
- Knowledge of pharmaceutical field force models, territory alignment principles, and target-setting guidelines is required.
- Solid knowledge of FFE tools, processes, performance-tracking methodologies, analytical frameworks, and the environment and operation of field teams in the China pharmaceutical industry is required.
- Strong communication skills to influence key stakeholders and collaborate with partner departments are required.
- Business judgment to identify priority performance bottlenecks is required.
- Strong analytical skills to conduct a wide range of analyses independently and collaboratively are required.
- The ability to develop solutions within complex business environments and processes is required.
- The ability to navigate cross-team dynamics and drive influence and impact is required.
- The ability to learn and adapt to a rapidly changing industry environment and practices is required.
- The ability to work under pressure and potentially work overtime to deliver high-quality work on time is required.
- Good command of written and spoken English is required.
- Facilitate GBU/BU general managers' decision-making on field force strategy and execution excellence by creating and delivering data-driven analytical solutions, solving business problems, and providing end-to-end statistical approaches.
- Serve as an analytical advisor to GBU/BU teams to improve field force execution excellence and productivity.
- Provide insights and recommendations on GBU/BU execution planning, and build an effective execution-tracking system with the business unit.
- Manage the field force planning process for GBU/BU teams.
- Drive continuous customer-engagement transition by leveraging digital tools and new technology.
- Collaborate with GBU/BU teams, other CE teams, and supporting functions to improve FFE processes and activities.
- Support GBU/BUs with field force sizing and deployment plans aligned with business objectives.
- Provide methodologies, templates, tools, and analytical support for territory management, including target hospital identification and potential analysis, workload estimation, territory alignment, target setting, and listing planning.
- Apply insights and experience to ensure field force planning fits China's business context and aligns with business strategy.
- Lead quarterly and yearly field force planning cycles, including territory alignment and target setting, with GBU/BU teams, ensuring timely, quality delivery.
- Coordinate with GBU/BU teams and the FFE Incentive team on incentive design to align business priorities with incentive design.
- Work with GBU/BU teams to design and continuously improve execution frameworks for customer profiling, segmentation and targeting, customer interaction planning (calls, remote engagement, and events), and objective setting.
- Design execution-tracking mechanisms and reports, and monitor execution with GBU/BU management teams.
- Provide GBU/BU management with insights and recommendations on execution status, gaps, and improvement opportunities.
- Drive the ongoing execution-model transition with GBU/BU teams and work with digital and omnichannel teams inside and outside GBU/BU.
- Manage FFE-related dashboards for GBU/BU teams, including design, data collection, production, and delivery.
- Work with marketing and field force teams to understand business needs and translate them into analytical requirements.
- Provide routine and ad hoc analyses for GBU/BU management on execution excellence, productivity improvement, and resource allocation.
- Lead or coordinate key FFE projects with GBU/BU teams, such as customer segmentation and field force sizing.
- Manage day-to-day FFE operational support for GBU/BU teams.
- Coordinate with GBU/BU teams and other teams to improve field force operating systems for efficiency and effectiveness.
- Manage the FFE Analysis Team to ensure it provides quality support to GBU/BU teams.
- Be responsible for the professional development of the FFE Analysis Team.
- Specialty care experience is strongly preferred.
- Change management experience involving FFE transformation or evolution is preferred.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)